Featured Story | | | Friday, August 18, 2017 We all know that biotech M&A activity has been pretty sluggish in 2017, but new stats out from Bloomberg show just how quiet things have been. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | | | Save 15% on the FierceBiotech 2nd Drug Development Forum
90+ executive-level speakers share advanced partnership and pipeline strategies September 25-27 in Boston, MA. Learn to adapt to increased deal complexity, real world evidence, and digital technologies. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Friday, August 18, 2017 Five Prime Therapeutics has appointed Bryan Irving, Ph.D., as its SVP of research. Irving made his name in the industry in a decadelong stint at Genentech, during which he performed research that gave rise to anti-PD-L1 antibody Tecentriq. Friday, August 18, 2017 Medivir has offloaded the Chinese rights to its early-stage hepatitis C candidate to Ascletis. The deal continues the retreat from infectious diseases Medivir began after Gilead and others cornered the hepatitis C market. Friday, August 18, 2017 Just weeks after Celgene got a PD-1 drug from China’s BeiGene, Arcus Biosciences inked an $816 million deal to get a PD-1 candidate WuXi Biologics had developed under a contract with Chinese firm Gloria Pharmaceuticals. Thursday, August 17, 2017 Pfizer today won FDA approval for a new targeted drug for the treatment of relapsed or refractory acute lymphoblastic leukemia. The approval comes at a watershed moment for the disease with new treatment options on the horizon. Thursday, August 17, 2017 In this week's EuroBiotech Report, Vicarius raises $22 million, GlaxoSmithKline jilts Ionis, CellAct lands a $250 million deal and more. Friday, August 18, 2017 | By Pfizer alum Samantha Du's Zai Lab filed for a $115 million Nasdaq IPO to help push forward several in-licensed cancer meds in China, Takeda formed a wide-ranging drug discovery alliance with Stanford University, China's Fosun and Shanghai Pharma are aiming to take a stake in Arbor Pharma and more. Friday, August 18, 2017 USCF cardiovascular research leader Shaun Coughlin will join the Novartis Institutes for BioMedical Research, Novo Nordisk's China GM was promoted to lead the company's corporate operations and troubled Teva lost a key executive to small biotech Cavion. Plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. 2nd Strategic Partnerships for Drug Repurposing Oct 26-27 | Boston, MA 15th Annual Discovery on Target September 25-29, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
